Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8792301 | Journal of American Association for Pediatric Ophthalmology and Strabismus | 2017 | 5 Pages |
Abstract
Occlusion therapy remains the mainstay treatment of amblyopia, but its outcome is not assured or universally excellent. Many factors are known to influence treatment outcome, among which compliance is foremost. The occlusion dose monitor (ODM) removes one variable from the treatment equation, because it records the occlusion actually received by-rather than prescribed for-the child. Improvement observed can thus be quantitatively related to the patching received. This review summarizes the insights the ODM has provided to date particularly in elucidating the dose-response relationship. We are entering the era of personalized ophthalmology in which treatments will be tailored to the needs of the individual child and facilitated by the use of wearable monitors.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Catherine E. BMedSci (Orthoptics), PhD, Merrick J. BSc, PhD, Pantelis PhD, Alistair R. FRCS, FRCOphth,